WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Biden promises quick provision of additional arms to Ukraine in call with ZelenskyHow do private enterprises tackle challenges with innovation?Royals' Alec Marsh hit on throwing arm by line drive, leaves in 5th against Blue JaysPeter Andre reveals TWO names are 'in the running' for his newborn daughter as legal deadline loomsCivil lawsuit dismissed against former Texas Tech basketball player Pop IsaacsChina details regulations on nonKhloe Kardashian surprises her daughter True, 6, with second cat as a birthday giftXizang reports soaring exports of local agricultural specialties in Q1China reports general public budget spending near 7 tln yuan in Q1China reports general public budget spending near 7 tln yuan in Q1
3.8868s , 6500.921875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grandeur news portal